DOXFLY-MD is a powerful combination therapy featuring Doxofylline (SR) and Montelukast Sodium, engineered to provide comprehensive relief for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). This dual-action formulation is a key part of the MK Healthcare respiratory range, designed to address both airway constriction and allergic inflammation simultaneously. By combining a potent bronchodilator with a leukotriene receptor antagonist, DOXFLY-MD helps patients breathe easier and reduces the frequency of acute respiratory attacks.

The clinical effectiveness of DOXFLY-MD lies in its advanced pharmacological synergy. Doxofylline, a next-generation xanthine derivative, works by relaxing the smooth muscles of the bronchial tubes to widen the airways, but with a significantly lower risk of cardiac and central nervous system side effects compared to older xanthines. Complementing this, Montelukast Sodium blocks the action of leukotrienes?chemicals in the body that cause swelling in the lungs and tightening of the muscles around the airways. This combination ensures that patients receive both immediate bronchodilation and long-term protection against allergic triggers.

To ensure consistent therapeutic delivery and improved patient compliance, the Doxofylline in this formulation is provided in a Sustained Release (SR) format. This allows for a steady release of the medication into the bloodstream, maintaining optimal airway patency throughout the day and night with fewer doses. Manufactured in ISO and GMP-certified facilities, DOXFLY-MD tablets are protected by premium Alu-Alu packaging (10x10 Tablets), which serves as an airtight barrier against moisture and environmental degradation, guaranteeing the stability and potency of the active ingredients.

For pharmaceutical professionals and distributors, DOXFLY-MD is a high-demand product that strengthens any Pulmonary or Anti-allergic product portfolio. Backed by the manufacturing expertise of MK Healthcare in Chandigarh and Himachal, this formulation is ideal for PCD Pharma Franchise and third-party manufacturing. By offering DOXFLY-MD, healthcare partners can provide a reliable, science-backed solution for chronic respiratory management that focuses on safety, long-term efficacy, and a better quality of life for patients across North India.